Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
about
Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infectionsHealthcare-associated infections, infection control and the potential of new antibiotics in development in the USAClinical management of infections caused by multidrug-resistant EnterobacteriaceaeAntibiotics in the clinical pipeline at the end of 2015.New trends in aminoglycosides use.Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.Plazomicin: an investigational therapy for the treatment of urinary tract infections.Reversing resistance: The next generation antibacterials.Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and PerspectivesA review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosidesTreatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply "precision medicine" to antimicrobial chemotherapy?Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against Klebsiella pneumoniae Carbapenemase- and Extended-Spectrum-β-Lactamase-Producing Enterobacter SpecNew and alternative approaches to tackling antibiotic resistance.Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.Aminoglycoside therapy in infectious diseases.Current strategies for the treatment of complicated intraabdominal infections.New antibiotics for bad bugs: where are we?Combating multidrug-resistant Gram-negative bacterial infections.Escherichia coli sequence type 131: epidemiology and challenges in treatment.Management of Intra-abdominal Infections due to Carbapenemase-Producing Organisms.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Development of novel antibacterial drugs to combat multiple resistant organisms.In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.Emerging drugs for nosocomial pneumonia.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?Occurrence of aminoglycoside-modifying enzymes among isolates of Escherichia coli exhibiting high levels of aminoglycoside resistance isolated from Korean cattle farms.Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity.Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study.Amikacin: Uses, Resistance, and Prospects for Inhibition.Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
P2860
Q26859978-C0379CE5-1AC0-4092-8FCE-F5F730705F36Q26995305-3CBB8AE9-83B2-4A47-B31B-A826D62B8E26Q28246841-91CCD823-F8C0-45F3-BC62-3A45ECD04576Q30249262-80F4C65B-B0A3-4452-88EB-775BB5B35405Q33951177-D9FEC752-1401-4B82-8185-EBBEB55A51C6Q34058006-77ADC0F3-87E4-4558-97FC-1F50835AF65CQ34673393-464606F0-2AB3-4ED3-BBA4-3717154854D1Q35669688-7AEBE435-C050-4C57-9D26-841F2C5DA2E0Q36575916-5879D0CC-82DA-4B35-9C64-360E3EC29CB9Q36726249-79A4AB2C-599D-4BF9-9DBC-90F426CC10B8Q37146405-155A5622-9454-45A4-B252-3DFADD25ED1CQ37203715-97555364-3E34-4DFF-9A5A-3955E76A79D7Q37372123-11DD4941-21FA-4AE9-BF47-818249C92349Q37612977-D668B491-AB49-4184-9A1D-F708EE829297Q37712980-66DDA319-C83A-4F01-BDDD-D41CFDE686DBQ38112810-E797B663-9B44-4551-B55B-3AE52C0AA0F5Q38123247-B475A419-E09A-4C98-831C-FEBD44D5666CQ38132217-AEBE483B-F80C-42E6-A825-2698C1372A6BQ38161570-6DF38AED-DEA2-4E56-AD85-D2E7FB0781BDQ38201515-864498BC-6777-48EE-8197-FF6B23775280Q38240411-622B41CF-6205-4427-89AC-F31171BDFDF7Q38262205-A4347BB5-3375-4141-95D1-DDDD5EFF4857Q38350301-7E8922D9-7DEC-406D-AA78-07E9A1DE6BA9Q38679493-D30734D7-D5AB-46B3-B013-2BAAE6A01A86Q38878167-0F3A4681-7ACA-41EE-A062-A168F3EB6627Q38892589-CC8C4A23-3BA8-49D1-9F09-3D0715A1E605Q40163452-A9ACF06A-5D36-4641-A8C6-BDAF5C4771D4Q41110741-94D99FFC-EEFD-4DAE-A0C2-6A9245440593Q47139448-CFDDC222-ECDC-4824-833C-AF4B31E8F532Q48315975-6FC72C5A-35A0-4AEE-82B9-88AE8F09504FQ49598865-ABFA2AF3-8762-4386-8AE2-5FE3CAEDB198Q52744431-50A95DD2-5FF4-4FBB-BB73-88ED587F73C4Q58746821-23E8FA9A-A564-48F5-8A53-0976738D3C78
P2860
Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@ast
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@en
type
label
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@ast
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@en
prefLabel
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@ast
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@en
P2093
P2860
P1476
Activity of plazomicin (ACHN-4 ...... cter spp. from Athens, Greece.
@en
P2093
Athina Argyropoulou
Garyphalia Poulakou
George L Daikos
George Petrikkos
George Plakias
Ioanna Stefanou
Maria Souli
Mina Psichogiou
Theofano Panagea
Zoi Chrysouli
P2860
P304
P356
10.1179/1973947812Y.0000000015
P577
2012-08-01T00:00:00Z